Abstract Vitiligo is a chronic autoimmune disorder characterized by skin depigmentation. Nonculture epidermal suspension has emerged as a promising treatment for stable vitiligo. This article evaluates the efficacy and safety of nonculture epidermal suspension in patients with stable vitiligo. Fifty-one patients with stable vitiligo underwent nonculture epidermal suspension treatment between 2016 and 2022. Repigmentation was assessed at 1 month, 3 months, 6 months, and 1 year. Factors affecting outcomes were analyzed. The mean repigmentation was 68% (95% confidence interval: 62.7–73.9%) with 43.1% of patients achieving excellent repigmentation. Long-term follow-up (> 2 years) in 32 patients showed 78% maintained stable repigmentation. Minor adverse events occurred in 13.7% of patients with no serious complications reported. Nonculture epidermal suspension is an effective, simple, and safe procedure for stable vitiligo with sustained long-term results.
Prashant Baranwal (Thu,) studied this question.